|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction.
|
31808123 |
2020 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Age and MI were associated with impaired cardiac function accompanied by left-ventricular (LV) dilatation. mRNA expression of MMP-2 (7d: p < 0.05), TIMP-1 (7d: p < 0.05), TIMP-2 (7d: p < 0.05), Collagen-1 (3d and 7d: p < 0.05) and Collagen-3 (7d: p < 0.05) in LV non-infarcted myocardium was significantly higher in YM than in OM after MI.
|
30763602 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of IL-6, TNF-α, and inflammatory related molecules ICAM-1, VCAM-1, MMP-2 and -9, nuclear NF-kB, and iNOS, were elevated in MI-V.
|
30642049 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The rats suffering from MI had decreased survival rates and exhibited reduced levels of NO, high-density lipoprotein cholesterol, and lumen diameter, and Smad7 messenger RNA (mRNA) and protein expression; while had significantly increased ratio of heart weight or body weight, levels of ET-1, inflammatory factors, blood lipid indexes, vascular remodeling indexes, collagen volume fraction, vulnerable atherosclerotic plaque area, VCAM-1 and MMP-2 protein expression, TGF-β, Smad2, Smad3, and Smad4 mRNA and protein expression.
|
30317569 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aerobic exercise increased levels of serum netrin-1, myocardial netrin-1, and the DCC receptor and reduced the expression of myocardial MMP2 and MMP9 proteins, to improve the degree of fibrosis following myocardial infarction in rats.
|
30789913 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of matrix metalloproteinase 2 (MMP-2), MMP-9, collagen type I, α-smooth muscle actin (α-SMA), and transforming growth factor-β (TGF-β) were upregulated in ISO-induced MI in rats.
|
30977399 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, a dual functional MI-responsive hydrogel is fabricated for on-demand drug delivery to promote angiogenesis and inhibit cardiac remodeling by targeting upregulated matrix metalloproteinase-2/9 (MMP-2/9) after MI.
|
31408234 |
2019 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction.
|
30019466 |
2018 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR and confocal microscopy revealed that epicardial EPO treatment enhanced levels of intracardiac regenerative key indicators (SDF-1, CXCR4, CD34, Bcl-2, cyclin D1, Cdc2 and MMP2), induced transforming growth factor β (TGF-β)/WNT signaling in intramyocardial MSC niches through the direct activation of AKT and upregulation of upstream signals FOS and Fzd7, and augmented intracardiac mesenchymal proliferation 24 h after MI.
|
29752300 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
A similar trend was identified for the expression of NF-κB, IL-1β and MMP-2, which was significantly increased in the MI group compared with that in the sham group (P<0.01), while it was significantly decreased in the MG and PDTC groups compared with that in the MI group (P<0.01).
|
30112065 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Disease-free centenarians had significantly lower (all p < 0.01) serum biomarker levels than young patients with myocardial infarction (growth differentiation factor 15: 877 ± 299 vs. 1062 ± 358 pg/mL; matrix metalloproteinase (MMP)-1: 1.7 ± 0.9 vs. 3.2 ± 1.2 ng/mL; MMP-2 174 ± 38 vs. 214 ± 44 ng/mL; MMP-9 325 ± 73 vs. 407 ± 54 ng/mL; and carboxy-terminal telopeptide of collagen type I: 3.3 ± 1 vs. 4.2 ± 1.3 ng/mL).
|
30244779 |
2018 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We evaluated <sup>68</sup>Ga-DOTA-peptide targeting MMP-2/9 for the detection of gelatinase expression after myocardial infarction (MI) in rat.
|
27914007 |
2018 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MMP-2 expression is elevated in many cardiovascular pathologies (e.g., myocardial infarction, hypertensive heart disease) where tissue remodeling and inflammatory responses are perturbed.
|
30118342 |
2018 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of α-smooth muscle actin and collagen I/III was observed, whereas the levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 were decreased in the hearts of Dectin-2 knockout mice after MI.
|
28193608 |
2017 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
The index of low SIRT1 and high MMP2 respectively correlated with patients history of MI (ρ=0.3, p=0.01) and marginally with presence or history of atrial fibrillation (AF) (ρ=0.213, p=0.076).
|
28043667 |
2017 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that AIM depletion decreases the levels of M1 macrophages, which are a potent source of MMP-2 and 9, in the infarcted myocardium in the acute phase after MI by promoting macrophage apoptosis, and leads to a decrease in the incidence of cardiac rupture and improvements in survival rates.
|
29121663 |
2017 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
To address these limitations, we have developed a MMP-2 inhibitor delivery system that can be specifically delivered into infarcted hearts at early stage of MI to efficiently prevent MMP-2-mediated ECM degradation.
|
28731675 |
2017 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The aim of current investigation was to explore the potential association between the low-density lipoprotein receptor-related protein 1 (LRP1) and MMP-9 and MMP-2 spatiotemporal expression after MI.
|
28378397 |
2017 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher levels of MMP-2 (299.47 ± 117.61 ng/ml) and MMP-9 (93.56 ± 53.74 ng/ml) were determined in patients with myocardial infarction compared to the controls, in both cases P < 0.001.
|
24280140 |
2013 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
CTD_human |
Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction: involvement in fibrosis and apoptosis.
|
24358288 |
2013 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The matrix metalloproteinase 2-1575 gene polymorphism is associated with the risk of developing myocardial infarction in Mexican patients.
|
22785600 |
2012 |
|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction.
|
21142815 |
2011 |
|
Myocardial Infarction
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction.
|
17879021 |
2007 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction.
|
16310260 |
2006 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
RGD |
ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat.
|
11179039 |
2001 |